抗青光眼药物致眼表改变的活体共聚焦显微镜评估
本回顾性队列研究用活体共聚焦显微镜(IVCM)评估局部抗青光眼药物对青光眼患者眼表疾病(OSD)的影响。结果显示长期用药者OSDI评分升高,角膜树突状细胞密度增加,上皮翼细胞和基底细胞密度降低,且药物类别数量可预测树突状细胞密度增加。
要点
- 长期使用抗青光眼药物可加重眼表疾病症状和角膜微结构改变。
- β受体阻滞剂对角膜上皮和神经丛的细胞毒性大于前列腺素类似物。
- 用药类别数量显著预测角膜树突状细胞密度增加,呈剂量依赖。
核心结论
- 长期局部抗青光眼药物以剂量依赖方式加重青光眼患者眼表疾病严重程度。
- 用药眼不仅症状严重,还出现中央角膜炎症和角膜神经衰减的微结构改变。
研究设计与样本
- 纳入39只接受单药治疗的眼(前列腺素类似物28只、β受体阻滞剂11只)、28只接受3类或以上药物联合治疗的眼,以及11只无青光眼和眼表疾病的健康眼。
主要发现
- 长期用药患者平均OSDI评分显著高于对照组,表明眼表疾病加重。
- 用药眼平均树突状细胞密度显著增加,平均上皮翼细胞密度和基底细胞密度显著降低。
- β受体阻滞剂对角膜上皮和神经丛的细胞毒性显著大于前列腺素类似物。
- α受体激动剂与其他药物类别相比与更高的神经纤维密度显著相关。
- Rho相关蛋白激酶抑制剂与OSDI评分呈显著正相关,处方药物类别数量显著预测树突状细胞密度增加。
临床怎么用
- 临床医生应认识到抗青光眼药物对眼表的非预期影响。
- 对长期使用抗青光眼药物的患者,需关注眼表疾病症状和角膜微结构变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the impact of topical antiglaucoma treatment on the development of ocular surface disease (OSD) in glaucomatous eyes using in vivo confocal microscopy (IVCM). DESIGN: Retrospective clinical cohort study. Data were collected from October 2021 to January 2024. PARTICIPANTS: A total of 39 eyes receiving monotherapy of either a prostaglandin analog (28) or beta-blocker (11), 28 eyes receiving polytherapy of 3 or more unique pharmacologic classes, and 11 healthy eyes without glaucoma or OSD. Exclusion criteria included a prior history of corneal disease, corneal surgery or laser procedure, use of topical anti-inflammatory medication, or intraocular surgery or medication changes within the last 6 months. METHODS: Central corneal images were obtained using IVCM. Image grading was performed by 2 independent, masked observers. Ocular surface disease index (OSDI) surveys were collected from each patient. MAIN OUTCOME MEASURES: Dendritic cell density (DCD), epithelial wing cell (WCD) and basal cell density (BCD), nerve fiber density (ND), nerve tortuosity and reflectivity, and OSDI scores were compared among the treatment and control groups. Linear regression tests were performed to analyze the effect of type and quantity of pharmacologic classes prescribed, duration of antiglaucoma medication use, and glaucoma severity on the corneal parameters. RESULTS: Patients on chronic antiglaucoma medications had significantly higher mean OSDI scores as compared to control, indicating worsening OSD. Treated eyes demonstrated significantly increased mean DCD and significantly decreased mean WCD and BCD as compared to control. Beta-blockers induce significantly greater cytotoxic effect on the corneal epithelium and nerve plexus as compared to prostaglandin analogs. Alpha-agonists were significantly associated with higher ND compared to other pharmacologic classes. Rho-associated protein kinase inhibitors demonstrate a significant, positive relationship with OSDI scores. The number of pharmacologic classes prescribed significantly predicts increases in DCD. CONCLUSIONS: Chronic use of topical antiglaucoma medications greatly contributes to the severity of OSD amongst glaucoma patients in a dose-dependent manner. Patients treated with antiglaucoma medications not only have severe OSD symptoms but also microstructural anatomic changes to the central cornea, characterized by inflammation and corneal nerve attenuation. Clinicians should recognize the unintended effects of antiglaucoma medications on the ocular surface.
引用
- Carbonell BAC, Filho JAM, Giraldo JR, et al. In Vivo Microscopic Assessment of Ocular Surface Changes Induced By Antiglaucoma Medications. Am J Ophthalmol. 2026. PMID: 42551780. doi:10.1016/j.ajo.2026.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。